Chromatin remodeller CHD7 is required for GABAergic neuron development by promoting PAQR3 expression

Priyanka Jamadagni[1], Maximilian Breuer[1], Kathrin Schmeisser[2,†], Tatiana Cardinal[3], Betelhem Kassa[1], J Alex Parker[2,4] (iD), Nicolas Pilon[3,5,6] (iD), Eric Samarut[2,4] & Shunmoogum A Patten[1,3,*] (iD)

Abstract

Mutations in the chromatin remodeller-coding gene *CHD7* cause CHARGE syndrome (CS). CS features include moderate to severe neurological and behavioural problems, clinically characterized by intellectual disability, attention-deficit/hyperactivity disorder and autism spectrum disorder. To investigate the poorly characterized neurobiological role of *CHD7*, we here generate a zebrafish *chd7*$^{-/-}$ model. *chd7*$^{-/-}$ mutants have less GABAergic neurons and exhibit a hyperactivity behavioural phenotype. The GABAergic neuron defect is at least in part due to downregulation of the CHD7 direct target gene *paqr3b*, and subsequent upregulation of MAPK/ERK signalling, which is also dysregulated in *CHD7* mutant human cells. Through a phenotype-based screen in *chd7*$^{-/-}$ zebrafish and *Caenorhabditis elegans*, we show that the small molecule ephedrine restores normal levels of MAPK/ERK signalling and improves both GABAergic defects and behavioural anomalies. We conclude that *chd7* promotes *paqr3b* expression and that this is required for normal GABAergic network development. This work provides insight into the neuropathogenesis associated with CHD7 deficiency and identifies a promising compound for further preclinical studies.

Introduction

Heterozygous loss-of-function mutations in *CHD7* are the major cause of a rare congenital disorder termed CHARGE syndrome (CS), which stands for coloboma of the eye, heart defects, atresia choanae, retardation of growth and/or development, genital abnormalities and ear abnormalities (Pagon *et al*, 1981; Zentner *et al*, 2010; Janssen *et al*, 2012). The mutations are equally distributed along the coding region of *CHD7*, and the most prevalent types are nonsense mutations (44%), followed by frameshift deletions or insertions (34%) (Janssen *et al*, 2012). Although neurological abnormalities are not considered for clinical diagnosis of CS, many individuals with CS display moderate to severe neurological deficits, which include autism-like behaviour, obsessive–compulsive disorder, attention-deficit/hyperactivity disorder, anxiety, aggressivity and seizures (Hartshorne *et al*, 2005; Souriau *et al*, 2005; Johansson *et al*, 2006; Bergman *et al*, 2011; Hartshorne *et al*, 2017). Along these lines, *CHD7* mutations have been identified in patients with autism spectrum disorder (ASD) (O'Roak *et al*, 2012; Takata *et al*, 2018). These reports strongly suggest an important role for CHD7 in the development and functioning of the central nervous system. However, the precise mechanisms underlying the neurological deficits in CS remain poorly understood. A recent study reported anxious- and aggressive-like behaviours with increased expression of glycine transporters in adult *chd7* heterozygous mutant zebrafish, leaving however unexplored the molecular and cellular mechanisms of brain circuitry (Liu & Liu, 2020). Also, noteworthy, there are no pharmacological and/or genetic treatments to ameliorate/rescue CS-related neurological features. Current treatment options primarily focus on behavioural management as well as educational and physical therapies. Development of successful therapeutic strategies would benefit from the identification and targeting of causative factors.

Chd7$^{-/-}$ mice die *in utero* around embryonic day 10.5 (Van Nostrand *et al*, 2014), a stage incompatible for studying the role of CHD7 in the neuropathogenesis of CS. Additionally, *Chd7*$^{+/-}$ mice are viable and phenocopy a number of aspects of CS, but the full spectrum and severity of certain CS malformations are not seen

1   INRS- Centre Armand-Frappier Santé Biotechnologie, Laval, QC, Canada
2   Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
3   Centre d'Excellence en Recherche sur les Maladies Orphelines - Fondation Courtois (CERMO-FC), Université du Québec à Montréal (UQAM), Montréal, QC, Canada
4   Modelis inc., Montréal, QC, Canada
5   Département des sciences biologiques, Université du Québec à Montréal (UQAM), Montréal, QC, Canada
6   Département de pédiatrie, Université de Montréal, Montréal, QC, Canada
    *Corresponding author. Tel: +1 450 687 5010 ext 8864; E-mail: kessen.patten@inrs.ca
    †Present address: Max-Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany

(Payne *et al*, 2015). Yet, *Chd7*$^{+/-}$ mice, *Chd7* conditional knockout mice and other cellular and animal (*Drosophila*, zebrafish and *Xenopus*) models have provided insights on the general function of CHD7 (Schnetz *et al*, 2010; Patten *et al*, 2012; Ohta *et al*, 2016; Feng *et al*, 2017; Whittaker *et al*, 2017; Belanger *et al*, 2018). For instance, it has been shown that CHD7 is capable of both enhancing and inhibiting expression of embryonic stem cell genes (Schnetz *et al*, 2010). In that respect, CHD7 facilitates neural stem cell maintenance and proliferation in the developing brain (Ohta *et al*, 2016) and quiescence in the adult (Jones *et al*, 2015). It is also required for the formation of migratory neural crest cells (Bajpai *et al*, 2010; Okuno *et al*, 2017). CHD7 coordinates with the transcription factor SOX10 to regulate the initiation of myelinogenesis (He *et al*, 2016) and is required for oligodendrocyte precursor cell survival (Marie *et al*, 2018). Genetic inactivation of *Chd7* in cerebellar granule neuron (GN) progenitors leads to cerebellar hypoplasia in mice, due to impairment of GN differentiation (Feng *et al*, 2017; Whittaker *et al*, 2017) but these cerebellar defects did not alter the social behaviour in these mice (Whittaker *et al*, 2017). Although these recent findings point to an important role of CHD7 in brain development, the precise neural substrates that may contribute to CS-associated neurological deficits such as autistic traits and/or hyperactivity disorder remain poorly understood. Emerging evidence suggests that abnormalities in inhibitory GABAergic neurons development/function in the context of neurodevelopmental disorders are characterized by a shared symptomatology of ASD symptoms (Rubenstein & Merzenich, 2003; Coghlan *et al*, 2012). Whether such alterations in brain inhibitory neural networks underlie the neurological deficits in *CHD7* mutation-positive cases of CS is currently unknown.

The zebrafish is a powerful tool for studying neurological diseases including ASD (Stewart *et al*, 2014; Meshalkina *et al*, 2018). Here, we report the generation of a *chd7*$^{-/-}$ mutant zebrafish line and show that these animals exhibit altered number and positioning of GABAergic neurons in the brain and display a hyperactive behaviour phenotype. Using genetic, pharmacological and biochemical approaches, we unravel the molecular mechanisms by which *chd7* regulates GABAergic network development and behaviour in zebrafish. Finally, through a chemical-genetic screen, we identified ephedrine that effectively ameliorates behavioural anomalies as well as the GABAergic defects in *chd7* mutants. This study provides novel insights into the role of CHD7 in brain development and disease and has important translational implications.

Results

Zebrafish *chd7* mutants display phenotypic characteristics of CHARGE syndrome

To investigate the neurobiological function of CHD7, we generated a *chd7* knockout zebrafish line using CRISPR/Cas9 to target the helicase domain of the *chd7* gene (17th exon) for disruption. A positive founder transmitting a single nucleotide insertion causing a frame-shifting mutation was selected (Fig 1A). This mutation causes a premature stop codon 8 amino acids after the mutation site (Fig EV1A). To assess whether the mutant *chd7* transcript underwent nonsense-mediated decay upon that mutation, we performed qPCR. The relative abundance of *chd7* mRNA in mutant zebrafish was significantly decreased, suggesting a loss of mutant transcript via nonsense-mediated decay (Fig EV1B). While no major morphological differences were observed between wild-type (*chd7*$^{+/+}$) and heterozygous (*chd7*$^{+/-}$) fish (Fig 1B), the survival rate of homozygous (*chd7*$^{-/-}$) larvae sharply declined after 10 days postfertilization (dpf) (Fig 1C). Remarkably, *chd7*$^{-/-}$ zebrafish larvae displayed a small head phenotype (Fig 1D) compared with controls but nevertheless all the brain regions were fairly well-preserved in mutant fish (Fig EV1C). Additionally, *chd7*$^{-/-}$ zebrafish larvae exhibited a low frequency of pericardial oedema (20 %) (Fig EV1D), cranial cartilage malformations (Fig EV1E) and cranial nerve defects (Fig 1E). Notably, there were less arborizations of peripheral projections from the Vth cranial nerve in *chd7*$^{-/-}$ fish. Precisely, *chd7*$^{-/-}$ fish had reduced growth and branching of the peripheral axons, resulting in a significant decrease in the mean total length of the axon projections as compared to controls (Fig 1E). Strikingly, these phenotypic characteristics are hallmarks of CS (Hsu *et al*, 2014). Additionally, this new *chd7*$^{-/-}$ mutant fish recapitulates other anomalies previously reported in *chd7* morphants (Patten *et al*, 2012) and other *chd7* mutant zebrafish lines (Cloney *et al*, 2018; Liu *et al*, 2018), but with less pronounced cardiac defects and no apparent blindness, thereby making it an ideal model to investigate the pathogenic mechanisms underlying CS-associated neurological deficits. Behaviourally, *chd7*$^{-/-}$ larvae were significantly hyperactive compared with wild-type and *chd7*$^{+/-}$ fish larvae at 5dpf (Fig 1F and G). This hyperactive phenotype was particularly prominent and persistent during the dark cycles (Fig 1G).

GABAergic neuron differentiation is defective in *chd7*$^{-/-}$ mutants

A hyperactivity behavioural phenotype in ASD mouse (Lee *et al*, 2018) and zebrafish (Hoffman *et al*, 2016) models has been reported

---

Figure 1. Generation of a zebrafish *chd7* mutant using CRISPR/Cas9.

A   Chromatograms showing the confirmation a 1-nucleotide insertion mutation by Sanger sequencing.
B   Gross morphological analyses of control (*chd7*$^{+/+}$; top left image), heterozygous (*chd7*$^{+/-}$; bottom left image) and knockout mutants (*chd7*$^{-/-}$; images in right panel).
C   Kaplan–Meier survival plot showing low survival of *chd7* mutants after 12 dpf ($N = 5$).
D   Measurement of head size of control ($n = 12$) and mutants ($n = 14$) showing significantly smaller head size in *chd7*$^{-/-}$ fish (****$P < 0.0001$, Student's *t*-test).
E   Acetylated tubulin staining in 28 hpf controls (left) and mutants (right) showing severely affected outbranching of the trigeminal nerve (Vth cranial nerve). Notably, *chd7*$^{-/-}$ display reduced branching of the Vth cranial nerve (arrows) and axonal arborization in the tectal area. Graphs showing quantitative analyses of percentage ($n = 5$) and mean total length of peripheral projections ($n = 6$) per zebrafish in controls and mutants (***$P < 0.001$; **$P < 0.005$, Student's *t*-test).
F   Locomotor activity of control (black), heterozygous (blue) and mutants (red) showing significant hyperactivity of mutants in dark and light cycles ($N = 3$, $n = 48$).
G   Average activity per second during dark cycle (left) is significantly increased in *chd7*$^{-/-}$ mutants compared with *chd7*$^{+/+}$ ($n = 32$; ****$P < 0.0001$, Student's *t*-test). Representative swimming tracks during dark cycle of control and mutant fish (right). Mutant *chd7*$^{-/-}$ larvae displayed hyperactive swimming.

Data information: ****$P < 0.0001$; ***$P < 0.001$; **$P < 0.005$, Student's *t*-test. Data are presented as mean ± SEM. Scale bar = 50 μm. *n* represents number of fish. *N* represents number of experimental repeats.

Figure 1.

to be due to alterations in GABAergic interneuron development. To test whether similar alterations in GABAergic neuron development occur in $chd7^{-/-}$ mutants, we analysed the inhibitory GABAergic neuronal populations in wild-type controls and $chd7^{-/-}$ mutants during early brain development (Fig 2), using a transgenic line that labels GABAergic interneurons (Tg(*dlx5a/6a:GFP*)). Compared with controls, $chd7^{-/-}$ larvae had a significant reduction in the density of GFP-positive GABAergic cells in the brain at 5 dpf (Fig 2A and B). Particularly, we observed a highly significant decrease in the number of GABAergic neurons in the optic tectum (OT) (Fig 2C and D) and a near-complete loss of GFP-positive cells in the cerebellum (CB) compared with the controls. Reduced number and malpositioning of GABAergic cells were also observed in the hypothalamus (HYP; Fig 2E and F) and telencephalon (TEL; Fig 2G and H).

We also examined the development of GABAergic neurons in $chd7^{-/-}$ brain throughout major developmental phases between 1 and 5 dpf (Fig EV2A). The reduced number of GFP-positive GABAergic neurons occurs very early in $chd7^{-/-}$ embryos, with a striking decrease of GABAergic neurons posteriorly between 1 and 2 dpf (Fig EV2A). We next tested whether the reduced number of GABAergic neurons in $chd7^{-/-}$ fish could be due to reduced proliferation, defects in neuronal differentiation and/or enhanced cell death. The zebrafish CNS proliferative profile is still very high at 2 dpf and is rapidly downregulated up to 5 dpf (Wullimann & Knipp, 2000). At 2 dpf, we did not observe a change in either the proliferation marker pH3 (Fig EV2B and C) or differences in the number of apoptotic cells (Fig EV2D). Additionally, we did not notice differences in the number of double-positive cells in pH3 and NeuroD1 (neuronal progenitor marker) co-staining (Fig EV2E). However, at 5 dpf, while no apoptosis was observed, a significant increase in pH3-positive cells was detected (Fig EV2F–H), suggesting a failure in differentiation of progenitor cells into GABAergic neurons.

We, thus, next sought to evaluate further neurogenesis in $chd7$ mutants during brain development, with a focus on the midbrain region—the brain region where the reduced number of GABAergic neurons was more prominent in 5 dpf $chd7^{-/-}$ fish. Zebrafish larvae (4 dpf) were exposed to BrdU-containing media for 24 h and fixed. In both $chd7^{+/+}$ and $chd7^{-/-}$ fish, BrdU-labelled cells were noted in the medial tectal proliferation zone (m), dorsal thalamus (DT), posterior tuberculum (PT) and the lateral tectal proliferation zone (l) of the midbrain (Fig EV3A and B). Interestingly, compared with $chd7^{+/+}$, BrdU-labelled cells in $chd7^{-/-}$ did not migrate over long distances to reach the early migrated region of pretectum and proglomerular (Fig EV3A; asterisks), which are regions involved with visual and other sensorimotor circuits (ref). We also found an increased in the number of BrdU-labelled cells in $chd7$ mutant fish compared with wild-type controls (Fig EV3C).

In order to determine the phenotype of BrdU-positive cells after the 24-h incubation period, brain sections were double-labelled to detect the colocalization of BrdU with HuC/D (a neuronal marker; Fig EV3A, B, D and E), *dlx5a/6a*-GFP (a GABAergic neuron marker; Fig EV3F and G) or NeuroD1 (a neuronal progenitor marker; Fig EV4A–D) in the midbrain area of the 5 dpf zebrafish larvae. The number of cells positive for both BrdU and HuC/D (Fig EV3E), BrdU and *dlx5a/6a*-GFP (Fig EV3G) or BrdU and NeuroD1 (Fig EV4D) in the midbrain area, surrounding the proliferation zone m, of the 5 dpf larvae was significantly lower in the $chd7^{-/-}$ larvae, indicating suppressed neurogenesis and impaired GABAergic neuronal

differentiation in $chd7$ mutants. Noteworthy, we found no change in the expression of the early glial marker scl1a3 (*Glast* in mammals) between $chd7^{-/-}$ and control fish (Fig EV4E), suggesting no alterations in gliogenesis upon loss of $chd7$.

GABAergic dysfunction is the underlying cause of behavioural defects

The altered number of GABAergic neurons in the $chd7^{-/-}$ mutant zebrafish brain suggests that these fish may have abnormal neural network that subsequently gives rise to abnormal behavioural outputs. Indeed, a hyperactive behavioural phenotype during dark cycles in zebrafish has been closely linked to disturbances in GABAergic signalling (Hoffman *et al*, 2016). We thus attempted to rescue/ameliorate the night-time hyperactive phenotype by targeting GABA receptors with two agonists, muscimol and baclofen (targeting GABA-A and GABA-B receptors, respectively). Both agonists rescued the constitutive hyperactivity observed in $chd7^{-/-}$ mutants (Fig 2I). We further reasoned that if GABAergic signalling was perturbed in $chd7^{-/-}$ mutants, these animals would be more susceptible to show signs of seizure upon treatment with pentylenetetrazol (PTZ), a GABA-A receptor antagonist that induces seizures in rodents and zebrafish (Baraban *et al*, 2005; Watanabe *et al*, 2010). As expected, PTZ treatment induced more severe seizures in $chd7$ mutants compared with wild-type controls, for both the time of onset and overall locomotor activity during the 20-min test period (Fig 2J and K). Altogether, our findings provide strong evidence that neurodevelopmental GABAergic signalling deficits underlie behavioural defects in $chd7^{-/-}$ mutants.

Brain gene expression profile is altered in $chd7^{-/-}$ zebrafish

CHD7 controls DNA accessibility by remodelling chromatin via translocating nucleosomes, thereby influencing gene transcription of many genes in both a positive and negative manner (Martin, 2010; Schnetz *et al*, 2010; Bouazoune & Kingston, 2012). To identify the molecular pathways underlying the neurodevelopmental defects in $chd7^{-/-}$ mutants, we thus performed an unbiased transcriptomic (RNA-seq) analysis on zebrafish $chd7^{-/-}$ larval brains (5 dpf) compared with wild-type controls. This age was chosen to perform an exhaustive analysis of the molecular phenotype because it corresponds to a stage when the behavioural phenotype is distinct. We identified 1,251 genes expressed in the $chd7^{-/-}$ larval brain that were significantly up- (677 genes) or downregulated (574 genes; $P < 0.05$; Fig 3A, Dataset EV1). Gene ontology analysis revealed that several biological processes (Fig 3B) and molecular functions (Fig 3C) are enriched in the differentially expressed genes such as binding, signalling, catalytic activity, cellular process, metabolic process and biological adhesion. Using pathway analysis, the expression of the significantly dysregulated genes was mainly assigned to the following pathways: MAPK signalling, cell adhesion, calcium ion signalling, lipid transport, haem binding, tryptophan metabolism and sterol synthesis (Table EV1). Analysis of the chromatin immunoprecipitation-sequencing (ChIP-seq) datasets from the ENCODE Transcription Factor Targets project (Rouillard *et al*, 2016) revealed that many of the dysregulated genes within the above-listed pathways are likely direct targets of CHD7 in murine and human cell lines (Table EV1).

Figure 2. GABAergic neuron defects in zebrafish *chd7* mutant brain.

A　　Structural illustration of 5 dpf zebrafish brain from dorsal (top) and lateral (bottom) view (OB: Olfactory bulb, Tel: Telencephalon, OT: Optic tectum, CB: Cerebellum, HB: Hindbrain).

B　　5 dpf *dlx5a/6a* transgenic line showing GFP$^+$ GABAergic neurons are reduced in *chd7$^{-/-}$* mutants (bottom) in comparison with controls (top) in both dorsal (left) and ventral (right) view.

C–H　Total number of GABAergic neurons (GFP$^+$ cells) in (C, D) the optic tectum (OT) and cerebellum (CB) regions of 5 dpf wild-type and *chd7* mutant fish (n = 16; ****$P < 0.0001$; Student's unpaired *t*-test), (E, F) the hypothalamus (hyp) region (n = 10; *$P = 0.0182$; Student's *t*-test) and (G, H) the telencephalon (tel) (n = 7; *$P = 0.0347$; Student's *t*-test).

I　　Treatment of control (dark grey) and mutants (light grey) with GABA agonists Baclofen (N = 3, n = 24; ns, $P = 0.1427$; Student's *t*-test) and Muscimol (N = 3, n = 24; ns, $P = 0.3987$; Student's *t*-test) showing recovery of hyperactive locomotor activity in *chd7$^{-/-}$* mutants (vehicle: N = 3, n = 24, ****$P < 0.0001$; Student's *t*-test).

J　　Functional analysis of GABAergic signalling shows increased responsiveness to GABA antagonist PTZ in both onset and overall locomotor activity (n = 24; ****$P < 0.0001$; one-way ANOVA).

K　　Average locomotor activity between 2 dpf controls (black) and *chd7$^{-/-}$* mutants (red) shows increased activity after 3 mM PTZ exposure (n = 24; ***$P < 0.001$; two-way ANOVA).

Data information: Data are presented as mean ± SEM. Scale bar = 50 μm. *n* represents number of fish used. *N* represents number of experimental repeats.

Downregulation of *paqr3b* in *chd7⁻/⁻* zebrafish contributes to GABAergic defects via MAPK/ERK signalling

Among the identified dysregulated pathways, MAPK signalling caught our attention the most based on its well-known role in the pathogenesis of a wide range of neurodevelopmental disorders, including autism (Vithayathil *et al*, 2018). To complement our transcriptomic analysis, we thus decided to evaluate the status of MAPK/ERK signalling in *chd7⁻/⁻* mutant brains and determine whether alteration of this pathway contributes to the observed GABAergic and behavioural defects. We detected a significant increase of phospho-Erk1/2 (pERK) in 5 dpf *chd7* mutant brains compared with wild-type controls, using both Western blotting (Fig 3D) and immunostaining (Fig 3E). Additionally, treatment with a specific MEK/ERK inhibitor that prevents ERK phosphorylation (U0126) significantly increased the number of GABAergic neurons in *chd7⁻/⁻* brains (Fig 3F and G) and reduced the hyperactive locomotor phenotype in *chd7⁻/⁻* larvae (Fig 3H). Altogether, these data strongly suggest that CHD7 regulates GABAergic neuron development and behaviour via MAPK signalling.

Amongst the dysregulated genes in *chd7⁻/⁻* brains that were assigned to the MAPK signalling pathway, we noted that 6 of them (*paqr3b*, *flnb*, *nr4a1*, *dusp2*, *hspa8* and *dusp16*) were also identified as direct targets of CHD7 in murine and human cell lines tested in the ENCODE project (Table EV1). We further noted that *paqr3b*, an inhibitor of the MAPK/ERK signalling (Feng *et al*, 2007; Zhang *et al*, 2010), is normally highly expressed in the zebrafish brain (Fig EV5A and B), and the most dysregulated gene in our RNA-seq dataset (Table EV1). Using RT–qPCR, we confirmed the strong downregulation of *paqr3b* in *chd7⁻/⁻* mutant brains (Fig EV5C). Importantly, we also validated that this finding was relevant for human CS using previously described lymphoblastoid cell lines (LCLs) derived from a *CHD7* mutation-positive child and its unaffected parents (Bélanger *et al*, 2018). LCLs are especially useful for analysing molecular mechanisms relevant to CS (Bélanger *et al*, 2018). Accordingly, RT–qPCR analysis showed that *PAQR3* gene expression was robustly decreased in *CHD7* mutation-positive LCLs compared with parental control LCLs (Fig 4A), while ChIP-qPCR revealed that this decrease was associated with markedly reduced occupation of the *PAQR3* proximal promoter by CHD7 (Fig 4B and C). These observations in human LCLs thus confirm that CHD7 directly regulates the expression of *PAQR3*.

Human PAQR3 is a regulator of ER (endoplasmic reticulum)-to-Golgi transport (Cao *et al*, 2018) that is essential for maintaining cellular and physiological homeostasis (Feng *et al*, 2007). To indirectly test this key role of PAQR3 in the context of GABAergic neuron development, we treated wild-type zebrafish with the ER-to-Golgi transport blocker brefeldin A (BFA) (Donaldson *et al*, 1992). Using a low dose of BFA to affect ER-to-Golgi trafficking without inducing cell stress and death in wild-type zebrafish (Le Corre *et al*, 2014), we found that BFA treatment was sufficient to recapitulate the decreased number and malpositioning of GABAergic neurons observed in *chd7⁻/⁻* mutant brains (Fig 5A and B). Importantly, we found that overexpression of *paqr3b* mRNA in *chd7⁻/⁻* mutants partially rescued the GABAergic neuron development defects at 3 dpf (Fig 5C and D) as well as restored pERK level to basal wild-type level (Fig 5E). Of note, overexpression of *paqr3b* mRNA in zebrafish embryos did not alter their gross morphology and viability (Fig EV5D). Altogether, these findings strongly suggest that a CHD7-PAQR3-MAPK/ERK regulatory axis is especially important for proper development of GABAergic neurons.

Ephedrine restores MAPK/ERK signalling and rescues GABAergic defects and associated behavioural anomalies

We recently demonstrated the power of combining simple genetic models such as worm (*Caenorhabditis elegans*) and zebrafish (*Danio rerio*) for identifying neuroprotective compounds that can rapidly be translated into preclinical and clinical testing (Patten *et al*, 2017). In *C. elegans*, loss-of-function of *chd-7* (Fig EV6A) leads to significant impairment of swimming locomotion when compared to wild-type animals (Fig 6A), and reduced lifespan (Fig 6B). Locomotion of *C. elegans* is controlled by inhibitory GABAergic and excitatory cholinergic motor neurons (Zhen & Samuel, 2015). To visualize neurodevelopmental problems in these neurons, *unc-47*p::mCherry and *unc-17*p::GFP reporters for GABAergic and cholinergic motor neurons, respectively, were crossed into *chd-7* mutant animals (referred to *chd-7* mut hereafter). We found that GABAergic neurodevelopment is significantly impaired in *chd-7* mut when compared to wild-type animals at the L4 stage, whereas the cholinergic motor system seems not to be affected by a mutation in the *chd-7* gene (Fig 6C). Particularly, a major neurodevelopmental problem in *chd-7* mut consists of interrupted connections in the GABAergic neuronal network, as indicated by significantly more axonal gaps and axonal loss/breaks larger than 50 μm (Fig 6D–G). The numbers of GABAergic cell bodies (Fig 6H) and commissures (Fig 6I) are slightly but significantly decreased to 22 and 12, respectively, compared with 26 and 16 in healthy worms. These observed phenotypes in *chd-7* mut worms are strikingly similar to those we previously reported in

---

Figure 3. *chd7* regulates GABAergic neuron development via MAPK/ERK signalling.

Transcriptomic analysis was performed on dissected 5 dpf brains.

A   Volcano plot showing each gene plotted according to its log₂ fold change. All highly differentially expressed genes with $P < 0.05$ are in orange with fold change > 1.5.

B, C   Biological processes (B) and molecular function (C) that are enriched in the differentially expressed genes.

D   ERK activation by phosphorylation is increased in mutants as shown by Western blot quantification ($N = 4$; $***P < 0.005$; Student's *t*-test).

E   pERK immunohistochemistry showing increased ERK activation in the mutant brain ($N = 3$, $n = 8$).

F, G   Treatment with the ERK signalling inhibitor U0126 ameliorated the number of GABAergic neuron ($n = 10–15$; $**P < 0.05$; $****P < 0.0001$, one-way ANOVA).

H   Treatment with the ERK signalling inhibitor U0126 rescues locomotor hyperactivity phenotype in *chd7* mutant fish ($n = 8$ for *chd7⁺/⁺* and *chd7⁻/⁻*; $n = 16$ for U0126-treated fish; $****P < 0.0001$; ns, not significant, one-way ANOVA).

Data information: Data are presented as mean ± SEM. Scale bar = 50 μm. *n* represents number of fish used. *N* represents number of experimental repeats.

Figure 3.

several *C. elegans* genetic models for ASD (Schmeisser *et al*, 2017).

We next exploited the impaired locomotion phenotype in *chd-7* mut worms to perform a comprehensive drug screen with 3,850 compounds (Fig 6J). We identified 49 compounds with beneficial effects that partially corrected the impaired locomotion of *chd-7* mut worms (Table EV2). Based on their suggested function, these compounds could be clustered into six main categories (Fig 6K). From all positive substances, three that improved swimming movement particularly well were chosen for further investigation: fisetin, meloxicam and ephedrine. The compounds were retested in worms and validated in our zebrafish model (Fig 6J) at various concentrations ranging from 1 to 50 μM. We confirmed two active compounds in zebrafish and identified ephedrine as the most potent lead

Figure 4. CHD7 regulates PAQR3 expression in human cells.

A qPCR analysis of PAQR3 expression in a *CHD7* mutation-positive patient compared with parental controls set ($N = 4$; ****$P < 0.0001$; Student's *t*-test). Fold change was calculated according to the $2^{-\Delta\Delta C_t}$ method, using *HPRT1* and *RPS1* as housekeeping genes for normalization. All data were expressed as mean fold change $\pm$ SD across replicates, relative to control parents set to 1 (dotted line). *N* is the number of experimental repeats.

B Schematic view of *PAQR3* exon 1 and proximal promoter on chromosome 4 (hg19 assembly), obtained with the UCSC genome browser (https://genome.ucsc.edu/) and showing the sequence amplified in ChIP-qPCR assays in LCLs (thick black line) along with a previously described CHD7 ChIP-seq peak (thick grey line) and signal (green) in H1-hESC (ENCODE3).

C ChIP-qPCR assays in LCLs showing decreased occupation of CHD7 on the *PAQR3* proximal promoter in a *CHD7* mutation-positive patient ($N = 3$) compared with parental controls ($N = 6$); *$P < 0.05$; Student's *t*-test. All data were expressed as mean fold change $\pm$ SD. *N* is the number of experimental repeats.

compound. Ephedrine was found to significantly improve behavioural and GABAergic defects in both *C. elegans* (Fig 6L and M) and zebrafish (Fig 6N and O). Ephedrine also improved the Vth cranial nerve branching defects in zebrafish (Fig EV6).

To test whether ephedrine is exerting its beneficial effects by correcting the aberrant MAPK/ERK signalling in *chd7*[−/−] mutants, we examined the level of pERK in these fish at 5dpf and found a significant reduction upon ephedrine treatment (Fig 6P and Q). Our findings thus support a model whereby development of GABAergic neurons in zebrafish is regulated by *chd7* via MAPK/ERK signalling. However, ephedrine treatment did not affect the level of *paqr3b*

expression in *chd7*[−/−] mutants (Fig 6R), suggesting that ephedrine is acting downstream in the MAPK/ERK signalling cascade.

Discussion

Despite advances in genetic studies of CS, the underlying mechanisms for the neurological deficits in this disease remain poorly understood. In this study, we showed that loss-of-function of the chromatin remodeller-coding gene *chd7* disrupts normal number of the inhibitory GABAergic neurons in the zebrafish brain.

Figure 5. Zebrafish *paqr3b* regulates GABAergic neuron development.

A, B GABAergic neuron defects in wild-type fish treated with ER/Golgi traffic inhibitor BFA ($n = 9$; ****$P < 0.0001$; ns, not significant; one-way ANOVA).

C, D Overexpression of *paqr3b* mRNA improve the number of GABAergic neurons in 3dpf *chd7* mutant fish ($n = 7$ for *chd7*$^{-/-}$ and $n = 11$ for *chd7*$^{-/-}$ + *paqr3b* mRNA; ****$P < 0.0001$; **$P < 0.05$; One-way ANOVA). Of note, the rescue experiment was performed at 3 dpf given the transient nature of mRNA.

E ERK activation by phosphorylation in *chd7*$^{-/-}$ mutants was restored to normal levels upon overexpression of *paqr3b* mRNA shown by Western blot quantification ($N = 4$; **$P < 0.05$; One-way ANOVA, N is the number of experimental repeats).

Data information: Data are presented as mean ± SEM. Scale bar = 50 μm.

Importantly, we also discovered that these GABAergic neuron defects result in behavioural anomalies that occur via an ERK-dependent mechanism. Furthermore, through a phenotype-based drug screening strategy, we identified a clinically approved drug, ephedrine, which proved to be very effective at correcting increased MAPK/ERK signalling, GABAergic defects and behaviour deficits caused by *chd7* loss-of-function.

We observed a significant reduction in the number of GABAergic interneurons in the zebrafish *chd7*$^{-/-}$ brain during development. GABAergic interneurons play an essential role in neural circuitry and behaviour. Proper differentiation of GABAergic neurons during brain development is important for establishing anatomical and functional circuitry. We found that the hyperactivity behavioural phenotype of *chd7*$^{-/-}$ mutant fish could be suppressed by

Figure 6.

modulating GABAergic signalling with agonists. These findings suggest that the abnormal behaviour due to loss of *chd7* in our mutants is likely in part due to defects in GABAergic network development. Interestingly, our observations are consistent with an ASD-related phenotype recently described in zebrafish mutants of the ASD risk gene, *CNTNAP2* (Hoffman *et al*, 2016). Patients with CHARGE syndrome frequently exhibit autism-like behaviour (Hartshorne *et al*, 2005; Smith *et al*, 2005). Several studies have shown that GABAergic neurons and circuits are altered in ASD (Rubenstein & Merzenich, 2003; Coghlan *et al*, 2012) and the dysfunction of inhibitory GABAergic circuits has been proposed as a cause for ASD (Pizzarelli & Cherubini, 2011). Our work suggests that the overlapping symptom of autistic features in CS and ASD may share a common neurobiological pathway implicating improper GABAergic development and function.

Noteworthy, we did not observe any abnormalities in *chd7* heterozygous mutants at the larval developmental stages that we studied. This is likely due to some teleost-specific genetic compensation mechanisms occurring in heterozygous background. Such a lack of phenotype in the heterozygous mutant population has also been observed while modelling several autosomal dominant diseases in zebrafish such as Dravet syndrome, hyperekplexia and juvenile myoclonic epilepsy, where disease-related phenotypes are only recapitulated in a homozygous mutant (−/−) background (Samarut *et al*, 2018; Samarut *et al*, 2019; Sourbron *et al*, 2019). It is, however, plausible that CHARGE-related behavioural changes may occur in juvenile or adult *chd7* heterozygous mutants and this warrants further studies.

PAQR3 negatively regulates Raf/MEK/ERK signalling (Feng *et al*, 2007; Zhang *et al*, 2010). The downregulation of *paqr3b* expression in *chd7$^{-/-}$* fish likely results in overactive Raf/MEK/ERK signalling, and hyperphosphorylation of ERK subsequently has detrimental consequences on neuronal network development. Xu *et al* (2016) showed PAQR3-deleted mice display motor and behavioural abnormalities. It is thus possible that *paqr3b* is important for neural connectivity and motor function in vertebrates. Aberrant signalling

through the MAPK/ERK pathway is involved in the pathogenesis of neurodevelopmental syndromes that involve autism, intellectual disability, neurodevelopmental delay and seizures (Vithayathil *et al*, 2018). Perturbation in MAPK/ERK activity in *chd7$^{-/-}$* mutants is consistent with findings observed in genetic models of ASD. Recent work by Holter *et al* (2021) revealed that hyperactive ERK signalling during mouse development affects the number of GABAergic interneurons. In our study, we similarly observed that with inhibition of ERK phosphorylation ameliorated the defective behaviour and number of GABAergic neurons. However, other mechanistic pathways under the control of CHD7 may also be important in GABAergic network development and this warrants further investigation. Indeed, we showed that the number of GABAergic neurons in *chd7$^{-/-}$* fish can be rescued by overexpressing *paqr3b* mRNA. PAQR3 is a key player in regulating ER-to-Golgi transport (Cao *et al*, 2018) and perturbing the secretory pathway may affect neurogenesis.

Ephedrine is both an α- and β-adrenergic agonist (Vansal & Feller, 1999; Ma *et al*, 2007). Our findings showed that this adrenergic receptor agonist significantly reverses GABAergic defects as well as abnormal behaviour in our models. Adrenergic receptors (ARs), in particular α1-AR, have also been shown to play a critical role in regulation of neurogenesis (Gupta *et al*, 2009). For instance, in neonates, α1-ARs are important for the differentiation of neural progenitors into catecholaminergic neurons and GABAergic interneurons (Gupta *et al*, 2009). It has been suggested that α1-AR is required in the neuronal maturation stages of neurogenesis by regulating the levels of the *Dlx2*, *Mash1*, *NeuroD* and *bHlH* mRNA (Gupta *et al*, 2009). Importantly, α1-ARs colocalize with both GABAergic and NMDA receptor-containing neurons and are likely to be involved in their regulation (Papay *et al*, 2006). As previously shown (Ferraro *et al*, 1993), α1-ARs can modulate GABA release in the human cerebral cortex and they have also been shown to regulate CA1 GABAergic interneurons in the rat hippocampus (Bergles *et al*, 1996). Interestingly, AR agonist treatment can significantly increase the excitability of GABAergic interneurons (Bergles *et al*,

1996; Marek & Aghajanian, 1996; Kawaguchi & Shindou, 1998; Papay *et al*, 2006) while having a contrasting effect in pyramidal cells (Papay *et al*, 2006). An α_1-AR-mediated facilitation of spontaneous GABA release from interneurons has been observed in several brain regions (Bergles *et al*, 1996; Kawaguchi & Shindou, 1998). It is possible that the increase in GABAergic signalling by ephedrine in our model is likely one of the underlying mechanisms in ameliorating the phenotypic anomalies in *chd7* mutants. Ephedrine acts as both a direct and indirect sympathomimetic. Its primary mode of action is achieved indirectly, by inhibiting neuronal norepinephrine reuptake and by displacing more norepinephrine from storage vesicles (Wellman *et al*, 2003; Becker, 2012). In addition to norepinephrine, detection of dopamine has also been reported under ephedrine-stimulated conditions in the CNS (Ruwe *et al*, 1985). Interestingly, dopaminergic signalling has been shown to regulate GABAergic neuron development and motor behaviour in zebrafish (Souza *et al*, 2011). The next step will be to unravel ephedrine's exact target and mechanism of action in our *chd7* models to increase the number of GABAergic neurons and to ameliorate behaviour.

In conclusion, we show for the first time that *chd7* controls GABAergic network development in zebrafish brain via regulating *paqr3b*. We also provide novel insight on the pathogenic mechanisms—from molecular pathway to brain circuits and behaviour—associated with *chd7* loss-of-function with relevance to CS and ASD. Five of nine members of the CHD family proteins have been implicated in neurodevelopmental disorders (Goodman & Bonni, 2019). Our findings may additionally be relevant to other neurodevelopmental diseases such as autism and epilepsy with which mutations in chromatin remodellers such as *CHD8* and *CHD2* have been associated. In this study, we also identify a clinically approved compound and its action on MAPK/ERK signalling that may be therapeutic avenues to be further explored in CHARGE syndrome. Overall, our work suggests that *in vivo* drug screening and experimental analysis of simple genetic models could prove extremely valuable in understanding and perhaps ultimately aid in developing treatments for certain neurological features associated with CHD7 deficiency.

Materials and Methods

Zebrafish

Fish husbandry

Adult zebrafish (*D. rerio*) were maintained at 28°C at a light/dark cycle of 12/12 h in accordance with Westerfield zebrafish book (Westerfield, 1993). Embryos were raised at 28.5°C, and collected and staged as previously described (Kimmel *et al*, 1995). The zebrafish lines used in this study were wild-type, *chd7* mutants, Tg(*dlx5a/6a*:GFP) which was obtained from the laboratory of Marc Ekker and used to generate Tg(*dlx5a/6a*:GFP;*chd7$^{-/-}$*) fish. All experiments were performed in compliance with the guidelines of the Canadian Council for Animal Care and the local ethics committee of INRS. For imaging studies, pigment formation was blocked by adding 0.003% phenylthiourea (PTU) dissolved in egg water at 24 h after fertilization (hpf).

CRISPR/Cas9-generated mutagenesis

A guide RNA (gRNA) targeting the helicase domain of the *chd7* gene was designed using the online tool CRISPRscan (TGTATTCCTGC

TGTGCACAA<u>GGG</u>; PAM site underlined). Synthesis of gRNA and of Cas9 mRNA was performed as previously described (Swaminathan *et al*, 2018). *Cas9* mRNA was synthesized using the mMESSAGE mMACHINE T3 kit from pT3TS-nCas9n plasmid (Addgene #46757) linearized with Xba1. A volume of 1 nl containing a mix of 100 ng/µl *Cas9* mRNA and 30 ng/µl gRNA was injected into one-cell stage embryos using the Picospritzer III pressure ejector. Genotyping of *chd7$^{+/+}$* (wild-type), *chd7$^{+/-}$* (heterozygous) and *chd7$^{-/-}$* (homozygous) fish was performed by high-resolution melting (HRM) analysis using genomic DNA extracted by boiling larva/clipped caudal fin in 50 mM NaOH for 10 min and then neutralized in 0.1 M Tris–HCl (pH8).

Rescue experiment was performed using *paqr3b* (NM_001030148.2) zebrafish open reading frame cloned into a pCS2$^+$ expression vector. *In vitro* transcription was done using the SP6 message machine kit (Ambion), and 1 nl of *paqr3b* mRNA (40 ng/µl) was injected into the 1-cell stage embryos.

Gross morphology and survival assessment

Larvae (*chd7$^{+/+}$*, *chd7$^{+/-}$* and *chd7$^{-/-}$*) were assessed for their survival rate and morphological phenotypes. The sample sizes for the different genotypes were as follows: three different batches ($N = 5$) each batch containing 30 larvae ($n = 30$) for *chd7$^{+/+}$*, *chd7$^{-/-}$* larvae and $N = 3$, $n = 18$–19 for *chd7$^{+/-}$* larvae. Gross morphology was observed under a stereomicroscope (Leica S6E). The head size at 3 dpf was measured using the software, ImageJ. Briefly, a straight line was drawn between the lowest point of the otolith and the anterior end of the brain, around the upper jaw area.

Neuronal network analysis

To visualize the axonal tracts, fluorescent immunohistochemistry was performed using the marker acetylated α-tubulin (Sigma-Aldrich; Cat# T7451). 28 hpf fish were fixed in Dent's fixation (80% methanol and 20% DMSO) overnight (O/N) at 4°C. Samples were rehydrated in 75, 50 and 25% methanol in PBST for 30 min each. They were then washed 4 times in PBST for 30 min (twice under agitation and twice without followed by blocking in 10 % normal goat serum (NGS) and 2 % bovine serum albumin (BSA) in PBST for 1 h at room temperature (RT), under agitation). Primary acetyl-tubulin monoclonal mouse antibody was added to the blocking (1:500) and incubated overnight at 4°C. After washing the primary antibody at least six times 30 min in PBST and blocking for 1 h, the secondary antibody Alexa 488 goat anti-mouse (Sigma-Aldrich; Cat# SAB4600387) was added O/N at a ratio of 1:1,000. Secondary antibody was washed and samples are mounted laterally for 28 hpf. Imaging was done on confocal microscope (Zeiss LSM780). The projection images were semi-automatically traced with NIH ImageJ using the NeuronJ plug-in. The total length of processes in each individual embryo was subsequently measured and analysed.

Craniofacial cartilage staining

To visualize the craniopharyngeal cartilage, Alcian blue staining was applied. Larvae were fixed in 4% paraformaldehyde (PFA) in PBST (one pellet in 200 ml dH$_2$O and 0.1% Tween). Fish were fixed at 6 dpf for 5 h at RT. Then, the samples were dehydrated in methanol solution with increasing concentration; 25, 50 and 75% in PBST (10–15 min each) and stored at −20°C until use. Before the staining was started, the samples were rehydrated in the reverse

order of methanol concentrations for 15 min each. After three quick washes in PBST, the samples were incubated in 0.1% Alcian blue solution with 70% ethanol (EtOH) and 0.37% HCl for 2 h, under agitation. Then, they were washed in EtOH and HCl solution; three quick washes and then twice 15 min. The larvae were digested in 10% trypsin in 30% saturated borax water which was pre-warmed a 42°C. At the end, the samples were washed overnight at 4°C in 0.1% KOH in H_2O. The following day, they were washed in 0.25% KOH for 1 h and stored in 80% glycerol and 0.25% KOH solution at 4°C until being imaged. Imaging was done on the Leica stereomicroscope (Leica S6E).

Behavioural analysis

Larvae (5 dpf) were separated into single wells of a 96-well plate containing 200 µl of E3 media and habituated in the Daniovision® recording chamber (Noldus) for 1 h before start of experiment. Larval locomotor activity was monitored over light-dark cycles using the Daniovision® apparatus. Analysis was performed using the EthoVision XT12 software (Noldus) to quantify the total swimming distance in given hours and the locomotor activity per second.

GABAergic neurons: confocal imaging and data analysis

To image and quantify GABAergic neurons (dlx5a/6a:GFP⁺ neurons), zebrafish larvae (1, 2, 3 and 5 dpf) of Tg(dlx5a/6a:GFP;chd7⁺/⁺) and Tg(dlx5a/6a:GFP;chd7⁻/⁻) were fixed in 4% PFA for 2 h. Zebrafish larvae (1, 2 and 3 dpf) were ventrally mounted for brain imaging, and in case of 5 dpf larvae, the brains were first dissected and then dorsally or ventrally mounted for imaging. Z-stack images were taken using a Zeiss LSM780 confocal microscope (Carl Zeiss, Germany). GABAergic neurons (dlx5a/6a:GFP⁺ neurons) were counted in the brain regions of wild-type and mutant larvae manually and blindly using the Cell Counter plug-in for Fiji/Image J (NIH) Imaging software.

Bromodeoxyuridine (BrdU) labelling

Zebrafish larvae at 4 dpf were incubated in a 10 mM solution of BrdU (BD Biosciences; Cat# 550891) in fish water at a temperature of 28.5°C for 24 h. All of the larvae were then fixed at 5 dpf in 4% PFA O/N at 4°C and used to perform cryo-sections of the brain.

Zebrafish brain cryo-sections and double-immunohistochemistry

Fixed larvae (5 dpf) were given serial sucrose treatment with 15 and 30% sucrose in 1X PBS, till the larvae sank to the bottom. The fish brains were then cryo-sectioned (transverse section) in 10-micron-thick sections and dried at room temperature for 20 min, and frozen to store.

For the immunostaining, the 5 dpf zebrafish embryo brain sections were first post-fixed in acetone at −20°C for 20 min. The sections were then washed with PBS for 15 min and processed for epitope retrieval with Tris–HCl (pH 8.2, 50 mM) at 85°C for 6-min treatment (for HuC/D, NeuroD1) and additionally with HCl (4 N) at 37°C for 10 min followed by Sodium borate (0.1 M) washes for 20 min (for BrdU). Sections were then washed in 0.5% PBS-Triton for 30 min, blocked in 10% NGS for 1 h at room temperature and then incubated in primary antibodies: HuC/D at 1:50 (Invitrogen; A21271); NeuroD1 at 1:500 (Abcam; ab60704), BrdU at 1:250 (Abcam; ab152095) and anti-GFP at 1:250 (Invitrogen; GF28R) diluted in 5% NGS, 1% BSA in 0.1% PBS-Triton, O/N at 4°C. The following day sections were washed in 0.3% PBS-Triton and incubated with species-specific secondary antibodies coupled to Alexa Fluor 488 or 555 (Invitrogen) diluted in 0.1% PBS-Triton for 2–3 h at room temperature, followed by washes with 0.3% PBS-Triton and mounted in DAPI glue (Invitrogen; Cat# P36941).

For the quantitative analyses, cells stained for BrdU, NeuroD1, GFP (for Dlx5/6) or HuC in the zebrafish midbrain area were taken under 40× magnification with an oil immersion lens using a Zeiss confocal microscope (LSM780; Carl Zeiss, Germany). The images were then processed with ZEN software (Carl Zeiss). Stained cells in consecutive sections from three brains per genotype (N = 3) were counted using ImageJ (NIH) and used to calculate the total number of double-positive stained cells relative to BrdU-positive cells in each larval brain section. Of note, the total number of sections (n) used varied between experiments. Neuroanatomical designations are taken from the Atlas of Early Zebrafish Brain Development (Mueller & Wullimann, 2015).

Haematoxylin and Eosin staining

For Haematoxylin and Eosin staining, brain sections were post-fixed in 10% formol (Chaptec) for 5 min and rinsed with tap water. The sections were stained with Haematoxylin (StatLab) for 4 min, washed with alcohol-acid, and were rinsed with tap water. The sections were then soaked in saturated Lithium Carbonate solution for 10 s and then rinsed it with tap water. Finally, staining was performed with Eosin Y (StatLab) for 2 min, and mounted under coverslip with permount mounting media. Neuroanatomical designations are taken from the Atlas of Early Zebrafish Brain Development (Mueller & Wullimann, 2015).

Drug treatment

Drugs were purchased from Sigma-Aldrich, and stock solutions were prepared: Pentylenetetrazol (PTZ)—Muscimol-30 mM, Baclofen-15 mM, U0126-10 mg/ml and Brefeldin A(BFA)—10 mg/ml. Embryos were treated from 8 hpf for GABA agonists Muscimol and Baclofen, and at 2 dpf for 20 min with 3 mM PTZ (Sigma-Aldrich). For treatment with BFA, an established low dose concentration 3.56 µM (1 µg/ml; Sigma-Aldrich) without inducing cell stress and death in zebrafish was used and added at 24 hpf (Le Corre et al, 2014). For treatment with U0126, a non-toxic low dose of 4 µM (1.7 µg/ml; Sigma-Aldrich) concentration was used and added at 8 hpf (Hawkins et al, 2008; Guo et al, 2015). The water was replaced every day with fresh water containing final concentration of the drug, until the activity measurement and/or brain imaging. For the chemical genetic screens, zebrafish embryos from 8 hpf were treated with fisetin, ephedrine and meloxicam (1–50 µM; all purchased from Sigma-Aldrich) in E3 medium. The medium was replaced every day with fresh solution containing final concentration of the drug, until the locomotor activity measurement and/or imaging.

Western blotting

Larvae were collected at 5 dpf and placed in the dark for at least 1 hr, following which lysates were rapidly prepared by homogenization in high salt lysis buffer containing 150 mM NaCl, 50 mM Tris–HCl pH 7.5, 1% Triton, 0.1% SDS, 1% sodium deoxycolate and protease inhibitors cocktail (1:10, Sigma-Aldrich). The lysates were centrifuged at 18,300 g for 10 min at 4°C. The supernatant was collected, and protein concentration was estimated using Bradford assay (Bio-Rad). Western blotting was performed using 20 µg lysate

per sample which were resolved on a 7.5% SDS-polyacrylamide gel (Bio-Rad). After electrophoresis, proteins on the gel were electro-transferred onto PVDF mini-membranes (Bio-Rad). The membranes were blocked with 5% non-fat milk solution in 1X phosphate-buffered saline or with 5% bovine serum albumin (Sigma) in 1X Tris-buffered saline for immunoblotting with anti-ERK (1: 2,000, Cell Signaling Technologies; Cat# 9102) and anti-pERK (1: 2,000, Cell Signaling Technologies; Cat# 9101), respectively. Detection was performed using goat anti-mouse and goat anti-rabbit antibodies, respectively, conjugated with horseradish peroxidase. Bands were visualized with ECL and imaged using ChemiDoc (Bio-Rad).

TUNEL assay
Whole-mount TUNEL staining to determine apoptosis was performed on 2 and 5 dpf larvae as previously described (Jamadagni & Patten, 2019). Briefly, larvae were fixed in 4% PFA and then seri-ally dehydrated and rehydrated with 25, 50 and 75% MeOH in PBST (0.1% Tween) and rinsed with PBST several times. The embryos were then digested with Proteinase K (10 µg/ml) for 20 min, followed by rinses with PBST and re-fixed with 4% PFA for 20 min. This was followed by two quick washes and three long washes of 20 min. in PBST (1% Triton X), then were rinsed again with PBS and incubated in TUNEL reaction mix (as directed by the manufac-turers; Roche/Sigma-Aldrich) for 1 h at 37°C. The larvae were then mounted and imaged under a Zeiss LSM 780 confocal microscope.

Whole-mount fluorescence immunohistochemistry
Whole-mount fluorescence immunohistochemistry for proliferation (pH3 marker) was performed as previously described (Verduzco & Amatruda, 2011). Briefly, 2 and 5 dpf zebrafish larvae were fixed in 4% PFA overnight at 4°C. After fixation, the embryos were rinsed two times for 10 min each with PBST (0.1% Tween). They were then incubated with acetone (100%) at −20°C for 7 min. Following this, the larvae were rinsed with PBST (0.3% Triton X) and PBS-DT (1% BSA, 1% DMSO, 1% Triton X) and further blocked in 5% NGS in PBS-DT for 1 h. Primary antibody pAb Rabbit Anti-phospho-Histone H3 (Ser10) (1:250; Millipore, Cat# 06–570) was added to the blocking solution and incubated overnight at 4°C. The next day, larvae were rinsed with PBS-DT and secondary antibody (Alexa Fluor 488, 1:1,000; Invitrogen) was then added and incubated over-night at 4°C. Larvae were rinsed and imaged with a Zeiss LSM 780 confocal microscope.

For pERK staining, zebrafish larvae (5 dpf) were placed in the dark for 1.5–2 h prior to rapid fixation in 4% PFA O/N. The larvae were then rinsed multiple times with PBST (0.1% Tween) followed by incubation in acetone (100%) at −20°C for 15 min. The larvae were then rinsed with PBST (0.3% Triton X) and PBS-DT (1% BSA, 1% DMSO, 1% Triton X) and further blocked in 5% NGS in PBS-DT for 1 h. Primary antibody anti-phospho-ERK (1:500, Cell Signaling Technologies; Cat# 9101) was added to the blocking solution and incubated overnight at 4°C. The following day, larvae were rinsed with PBS-DT and incubated with secondary antibody (Alexa fluor 488, 1:1,000; Invitrogen) overnight at 4°C. Larvae were rinsed and imaged with a Zeiss LSM 780 confocal microscope.

Transcriptomic, differential expression and pathway analyses
Three independent batches of 5 dpf $chd7^{+/+}$ and $chd7^{-/-}$ larvae were dissected to extract the whole brain, by each of two experimenters,

corresponding to experimental triplicates. Total RNA was extracted from these flash-frozen brains using PicoPure RNA extraction kit (Thermo Fisher Scientific) following the manufacturer's standard protocol. For each sample, RNA extraction was made from five whole brains. The absence of contamination was assessed by Nano-drop using 260/280 and 260/230 ratios. Quality of total RNA was assessed with the BioAnalyzer Nano (Agilent), and all samples had a RIN above 8.3. Library preparation was performed using the TruSeq RNA (Illumina). Eight PCR cycles were required to amplify cDNA libraries. Libraries were quantified by Nanodrop and BioAna-lyzer. All libraries were diluted to 10 nM and normalized with the Miseq SR50 v2. Libraries were pooled to equimolar concentration and multiplexed by six samples per lane. Sequencing was performed with the Illumina Hiseq2000 using the SBS Reagent Kit v3 (100 cycles, paired-end) with 1.6 nM of the pooled library. Cluster density was targeted at around 800k clusters/mm^2. Between 75 and 140 million reads were generated for each sample. Library prepara-tion and sequencing was done at the genomics platform of the Insti-tute for Research in Immunology and Cancer (University of Montreal). More than 93% of high-quality reads were mappable onto the zv9 version of the zebrafish genome (ensemble release 77) using TopHat version 2.0.10. Differential gene expression analysis was assessed by DeSeq2 package using R software. Genes showing an absolute fold change >1.2 and an adjusted P value (false discov-ery rate) < 0.05 were considered to be significantly differentially expressed. Gene enrichment and pathway analysis were performed using PANTHER and DAVID bioinformatics resources (Huang da et al, 2009; Mi et al, 2019). The RNA-seq has been deposited to the GEO database (GSE139623).

RT–qPCR
RT–qPCR was performed as previously described in Breuer et al, (2019). In short, RNA was isolated from ~ 30 embryos using TriRea-gent® (Sigma) according to manufacturer's protocol. 1 µg of RNA was used for cDNA synthesis by SuperScript®Vilo™ kit (Invitrogen). RT–qPCR was run with SYBR Green Master Mix (Bioline) using the LightCycler® 96 (Roche). ef1a was used as the reference gene for normalization and following primers were used for paqr3b: FW: 5′ – CGCTGGCTTGCTCTGGATTA – 3′; RV:5′ – CCTGCCTCCAAAAACTG TTGC – 3′.

Lymphoblastoid cell lines

Cell culture
Lymphoblastoid cell lines (LCLs) from a CHD7 mutation-positive (c.5050+1G>T) CHARGE syndrome patient and its unaffected parents were maintained in RPMI medium as described previously (Belanger et al 2018). Families provided informed consent on stud-ies approved by the respective institutional review board of the Baylor College of Medicine (experimental cohort for this study).

RT–qPCR (LCLs)
Relative transcript levels of PAQR3 mRNA in LCLs were analysed by RT–qPCR. The RT–qPCR analyses were performed as described above. The following primers were used for PAQR3: (Forward) 5′-CCAATTACCTCACGCAGCAA- 3′ and (Reverse) 5′-GGAGCACCAA TTCCTCCATT- 3′. Fold change was calculated according to the $2^{-\Delta\Delta C_t}$ method, using HPRT1 and RPS1 as housekeeping genes for

normalization. All data were expressed as mean fold change ± SD across replicates, relative to control parents set to 1.

ChIP assays

ChIP-qPCR assays in 2×10^8 LCLs were performed as previously described (Belanger *et al*, 2018), using 2 µg of rabbit anti-CHD7 antibody (Cell Signaling; Cat# 6505) and 2 µg of rabbit anti-HA antibody (Abcam; Cat# ab9110) as negative control. Target sequence (196 bp) at the *PAQR3* proximal promoter was determined based on a previously described ChIP-seq peak of CHD7 in H1-hESC (Sethi *et al*, 2020) that was downloaded from the ENCODE portal (Sloan *et al*, 2016) (https://www.encodeproject.org/); the relevant track (#ENCFF628RLE) was visualized on the UCSC genome browser using the GRCh37/hg19 human assembly (https://genome.ucsc.edu/). Primer sequences were: (Forward) 5′- GCT ACA GGC GAA TAC AAG TGG - 3′ and (Reverse) 5′- CTG ACT TCA GCT TAG AAA TCC TC - 3′). ChIP-qPCR efficiency was calculated in % of CHD7 IP relative to input and expressed in fold enrichment relative to HA negative control.

Caenorhabditis elegans

Caenorhabditis elegans strains and maintenance

Caenorhabditis elegans was handled applying standard conditions (Stiernagle, 2006). Worms were kept on NGM agar with an *Escherichia coli* OP50 lawn at 15°C for maintenance and 20°C for assays. The mutant strain *chd-7(gk290)* (VC606) was provided by the Caenorhabditis Genetics Center at the University of Minnesota and backcrossed four times to N2 wildtype (WT).

Caenorhabditis elegans locomotion assay

A worm tracking machine (*Wmicrotracker*, Phylum Tech) was used to track the swimming locomotion of *C. elegans*. Assays were performed in 96-well-microtiter plates with approximately 30 worms and 100 µl M9 buffer per well. *Escherichia coli* OP50 were added to the wells to prevent worms from starving. Each microtitre well was crossed by two infrared light rays from top to bottom and a detector determined interruptions of these light rays by worms moving in the well. From the signal, a movement score was calculated, which is defined as animal movement in a fixed time period. Movement was tracked for 10 h. The assay was performed in triplicates and movement scores of *chd-7(gk290)* over time were compared with WT in three independent experiments using two-tailed *t*-test to determine significance.

Drug libraries

Natural and FDA-approved compounds were provided by Sigma-Aldrich (Sigma-Aldrich's Library of Pharmacologically Active Compounds (Lopac) 1280 library, containing compounds as of July 2015, Oakville/Canada), Prestwick Chemicals (Prestwick Chemical Library; containing compounds as of March 2015, Illkirch/France), MicroSource (880 compounds, Gaylordsville, CT/USA), Enzo Life Science, Inc. (BML-2865 Natural Products Library, containing compounds as of April 2015, Farmingdale, NY/USA). All compounds were dissolved in DMSO and tested at a concentration of 20 µM.

Drugs screen in C. elegans

Chd-7(gk290) nematodes were exposed to the drugs from the libraries in microtitre wells at a concentration of 20 µM in M9 buffer with OP50

and movement was tracked for at least 4 h. The average movement score of *C. elegans* treated with a specific drug was compared with the DMSO control and the average movement score of the whole plate. If values for a drug were higher than the respective controls, a second screen to validate the increased movement due to the specific drug was performed. Compounds that increased locomotion of *chd-7 (gk290)* significantly according to a two-tailed *t*-test in the second screen were counted as positive. A complete list of all drugs tested can be found in reference (Schmeisser & Parker, 2017).

Assessment of neuronal integrity of GABAergic and cholinergic motor neurons in C. elegans

An *unc-47*p::mCherry and *unc-17*p::GFP reporter for GABAergic and cholinergic motor neurons was crossed into *chd-7(gk290)* to analyse motor neurodevelopment at the L4 stage *in vivo*. Worms were put on microscopy slides with 2% agarose pads, paralysed with 5 mM levamisole and covered with a coverslip. Neuronal examinations were performed with a Zeiss Axio Imager M2 microscope (*unc-47*::mCherry) and a Leica DM6000 microscope (*unc-17*p::GFP). About 100 worms were analysed in four independent experiments and compared with WT.

For a more detailed neuronal status in *chd-7(gk290)*, neuronal morphology was categorized into the following groups: gaps in the axonal branches per animal, number of axon commissures per animal, number of GABAergic and cholinergic cell bodies, and frequency of breaks > 50 µm in the nerve cords, which goes along with massive loss of neuronal tissue. About 30 *chd-7(gk290)* worms with dysmorphic neuronal morphology were scored and compared with the neuronal morphology of WT worms.

Testing of beneficial compounds identified in the drug screen was performed as follows: NGM agar plates containing 20 µM of the respective substance were freshly prepared prior to each assay and seeded with OP50. Young adult *C. elegans* were allowed to lay eggs for about 4 h, and assays for neuronal morphology were performed in the progeny at the L4 stage as described above. Mean ± standard deviation of three independent experiments were calculated and two-tailed *t*-tests determined significance. Gaps in axonal branches, number of axon commissures, cell bodies and breaks > 50 µm in the nerve chords were determined in three independent experiments. Average and standard deviation of all tested animals were calculated and two-tailed *t*-tests were performed.

Caenorhabditis elegans lifespan assay

Lifespan assays were performed as previously described (Schmeisser *et al*, 2013). Briefly, worms were synchronized at the egg stage (day 0) and about 50 nematodes were transferred to each of three fresh lifespan plates per condition at the L4 stage. Worms were transferred on plates containing 10 µM FUDR (solved in water; applied on top of the grown bacteria lawn) after 24–48 h to prevent contamination with progeny generations. Nematodes that did not react to repeated gentle stimulation were scored as dead. Non-natural deaths (bagging, protrusive vulvae) and lost animals were censored. JMP 11.0.0 (SAS Institute Inc.) was used for statistical analyses, and the log-rang test determined *P* value and significance.

Statistical analysis

All zebrafish experiments were performed on at least three replicates (*N*) and each consisted of a sample size (*n*) of 8–30 fish. All *C.*

elegans experiments have been performed for a minimum of three biological replicates. The number of samples was determined empirically. Data are presented as Mean ± SEM. Significance was determined using either Student's *t*-test, one-way ANOVA or two-way ANOVA using GraphPad PRISM software. All graphs were plotted using the GraphPad PRISM software.

Data availability

The RNA-seq has been deposited to the GEO database (GSE139623). (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139623).

Expanded View for this article is available online.

Author contributions

SAP conceived this work. PJ designed, collected, analyzed and interpreted the results from studies related to GABAergic neurons and behaviour in zebrafish. ES, MB collected and analyzed the results of RNAseq. KS collected, analyzed and interpreted the results from studies related to *C. elegans* experiments. BK, SAP generated and characterized the CRISPR *chd7* mutant line. PJ and BK performed the drug analyses in zebrafish. TC performed the ChIP analyses. PJ, MB, KS, JAP, ES, TC, NP and SAP interpreted the results. JAP, NP and SAP secured the research funding. PJ, KS, TC, NP and SAP drafted the manuscript. PJ and SAP with contributions from all authors prepared the final version of the manuscript. All authors read the final version of this manuscript.

Conflict of interest

The authors declare no competing interests. ES and JAP are co-founders of Modelis Inc. The commercial affiliations did not play any role in this study; in particular, they did not have any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

References

Bajpai R, Chen DA, Rada-Iglesias A, Zhang J, Xiong Y, Helms J, Chang CP, Zhao Y, Swigut T, Wysocka J (2010) CHD7 cooperates with PBAF to control multipotent neural crest formation. *Nature* 463: 958–962

Baraban SC, Taylor MR, Castro PA, Baier H (2005) Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. *Neuroscience* 131: 759–768

Becker DE (2012) Basic and clinical pharmacology of autonomic drugs. *Anesth Prog* 59: 159–169

Belanger C, Berube-Simard FA, Leduc E, Bernas G, Campeau PM, Lalani SR, Martin DM, Bielas S, Moccia A, Srivastava A *et al* (2018) Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome. *Proc Natl Acad Sci USA* 115: E620–E629

Bergles DE, Doze VA, Madison DV, Smith SJ (1996) Excitatory actions of norepinephrine on multiple classes of hippocampal CA1 interneurons. *J Neurosci* 16: 572–585

Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, van Ravenswaaij-Arts CM (2011) CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. *J Med Genet* 48: 334–342

Bouazoune K, Kingston RE (2012) Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders. *Proc Natl Acad Sci USA* 109: 19238–19243

Breuer M, Guglielmi L, Zielonka M, Hemberger V, Kolker S, Okun JG, Hoffmann GF, Carl M, Sauer SW, Opladen T (2019) QDPR homologues in *Danio rerio* regulate melanin synthesis, early gliogenesis, and glutamine homeostasis. *PLoS One* 14: e0215162

Cao Q, Wang Z, Wan H, Xu L, You X, Liao L, Chen Y (2018) PAQR3 regulates endoplasmic reticulum-to-golgi trafficking of COPII vesicle via interaction with Sec13/Sec31 Coat proteins. *iScience* 9: 382–398

Cloney K, Steele SL, Stoyek MR, Croll RP, Smith FM, Prykhozhij SV, Brown MM, Midgen C, Blake K, Berman JN (2018) Etiology and functional validation of gastrointestinal motility dysfunction in a zebrafish model of CHARGE syndrome. *FEBS J* 285: 2125–2140

Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ (2012) GABA system dysfunction in autism and related disorders: from synapse to symptoms. *Neurosci Biobehau Rev* 36: 2044–2055

Donaldson JG, Finazzi D, Klausner RD (1992) Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. *Nature* 360: 350–352

Feng L, Xie X, Ding Q, Luo X, He J, Fan F, Liu W, Wang Z, Chen Y (2007) Spatial regulation of Raf kinase signaling by RKTG. *Proc Natl Acad Sci USA* 104: 14348–14353

Feng W, Kawauchi D, Korkel-Qu H, Deng H, Serger E, Sieber L, Lieberman JA, Jimeno-Gonzalez S, Lambo S, Hanna BS *et al* (2017) Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. *Nat Commun* 8: 14758

Ferraro L, Tanganelli S, Calo G, Antonelli T, Fabrizi A, Acciarri N, Bianchi C, Beani L, Simonato M (1993) Noradrenergic modulation of gamma-aminobutyric acid outflow from the human cerebral cortex. *Brain Res* 629: 103–108

Goodman JV, Bonni A (2019) Regulation of neuronal connectivity in the mammalian brain by chromatin remodeling. *Curr Opin Neurobiol* 59: 59–68

Guo M, Wei H, Hu J, Sun S, Long J, Wang X (2015) U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. *Oncol Rep* 34: 699–706

Gupta MK, Papay RS, Jurgens CW, Gaivin RJ, Shi T, Doze VA, Perez DM (2009) alpha1-Adrenergic receptors regulate neurogenesis and gliogenesis. *Mol Pharmacol* 76: 314–326

Hartshorne TS, Grialou TL, Parker KR (2005) Autistic-like behavior in CHARGE syndrome. *Am J Med Genet A* 133A: 257–261

Hartshorne TS, Stratton KK, Brown D, Madhavan-Brown S, Schmittel MC (2017) Behavior in CHARGE syndrome. *Am J Med Genet C Semin Med Genet* 175: 431–438

Hawkins TA, Cavodeassi F, Erdelyi F, Szabo G, Lele Z (2008) The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish. *BMC Dev Biol* 8: 42

He D, Marie C, Zhao C, Kim B, Wang J, Deng Y, Clavairoly A, Frah M, Wang H, He X *et al* (2016) Chd7 cooperates with Sox10 and regulates the onset of CNS myelination and remyelination. *Nat Neurosci* 19: 678–689

Hoffman EJ, Turner KJ, Fernandez JM, Cifuentes D, Ghosh M, Ijaz S, Jain RA, Kubo F, Bill BR, Baier H *et al* (2016) Estrogens suppress a behavioral phenotype in zebrafish mutants of the autism risk gene, CNTNAP2. *Neuron* 89: 725–733

Holter MC, Hewitt LT, Nishimura KJ, Knowles SJ, Bjorklund GR, Shah S, Fry NR, Rees KP, Gupta TA, Daniels CW *et al* (2021) Hyperactive MEK1 signaling in cortical GABAergic neurons promotes embryonic parvalbumin neuron loss and defects in behavioral inhibition. *Cereb Cortex* https://doi.org/10.1093/cercor/bhaa413

Hsu P, Ma A, Wilson M, Williams G, Curotta J, Munns CF, Mehr S (2014) CHARGE syndrome: a review. *J Paediatr Child Health* 50: 504–511

da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4: 44–57

Jamadagni P, Patten SA (2019) 25-hydroxycholesterol impairs neuronal and muscular development in zebrafish. *Neurotoxicology* 75: 14–23

Janssen N, Bergman JE, Swertz MA, Tranebjaerg L, Lodahl M, Schoots J, Hofstra RM, van Ravenswaaij-Arts CM, Hoefsloot LH (2012) Mutation update on the CHD7 gene involved in CHARGE syndrome. *Hum Mutat* 33: 1149–1160

Johansson M, Rastam M, Billstedt E, Danielsson S, Stromland K, Miller M, Gillberg C (2006) Autism spectrum disorders and underlying brain pathology in CHARGE association. *Dev Med Child Neurol* 48: 40–50

Jones KM, Saric N, Russell JP, Andoniadou CL, Scambler PJ, Basson MA (2015) CHD7 maintains neural stem cell quiescence and prevents premature stem cell depletion in the adult hippocampus. *Stem Cells* 33: 196–210

Kawaguchi Y, Shindou T (1998) Noradrenergic excitation and inhibition of GABAergic cell types in rat frontal cortex. *J Neurosci* 18: 6963–6976

Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF (1995) Stages of embryonic development of the zebrafish. *Dev Dynam* 203: 253–310

Le Corre S, Eyre D, Drummond IA (2014) Modulation of the secretory pathway rescues zebrafish polycystic kidney disease pathology. *J Am Soc Nephrol* 25: 1749–1759

Lee S, Lee E, Kim R, Kim J, Lee S, Park H, Yang E, Kim H, Kim E (2018) Shank2 deletion in parvalbumin neurons leads to moderate hyperactivity, enhanced self-grooming and suppressed seizure susceptibility in mice. *Front Mol Neurosci* 11: 209

Liu ZZ, Wang ZL, Choi TI, Huang WT, Wang HT, Han YY, Zhu LY, Kim HT, Choi JH, Lee JS *et al* (2018) Chd7 Is critical for early T-cell development and thymus organogenesis in zebrafish. *Am J Pathol* 188: 1043–1058

Liu H, Liu ZZ (2020) Aggressive-like behavior and increased glycine transporters in a zebrafish model of CHARGE syndrome. *Behav Brain Res* 378: 112293

Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR (2007) Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. *J Pharmacol Exp Ther* 322: 214–221

Marek GJ, Aghajanian GK (1996) Alpha 1B-adrenoceptor-mediated excitation of piriform cortical interneurons. *Eur J Pharmacol* 305: 95–100

Marie C, Clavairoly A, Frah M, Hmidan H, Yan J, Zhao C, Van Steenwinckel J, Daveau R, Zalc B, Hassan B *et al* (2018) Oligodendrocyte precursor survival and differentiation requires chromatin remodeling by Chd7 and Chd8. *Proc Natl Acad Sci USA* 115: E8246–E8255

Martin DM (2010) Chromatin remodeling in development and disease: focus on CHD7. *PLoS Genet* 6: e1001010

Meshalkina DA, N. Kizlyk M, V. Kysil E, Collier AD, Echevarria DJ, Abreu MS, Barcellos LJG, Song C, Warnick JE, Kyzar EJ *et al* (2018) Zebrafish models of autism spectrum disorder. *Exp Neurol* 299: 207–216

Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD (2019) PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res* 47: D419–D426

Mueller T, Wullimann MF (2015) *Atlas of Early zebrafish brain development: a tool for molecular neurogenetics*, 2nd edn, pp 258. Amsterdam: Elsevier

Ohta S, Yaguchi T, Okuno H, Chneiweiss H, Kawakami Y, Okano H (2016) CHD7 promotes proliferation of neural stem cells mediated by MIF. *Mol Brain* 9: 96

Okuno H, Renault Mihara F, Ohta S, Fukuda K, Kurosawa K, Akamatsu W, Sanosaka T, Kohyama J, Hayashi K, Nakajima K *et al* (2017) CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations. *eLife* 6: e21114

O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD *et al* (2012) Sporadic autism exomes reveal a highly interconnected protein network of *de novo* mutations. *Nature* 485: 246–250

Pagon RA, Graham Jr JM, Zonana J, Yong SL (1981) Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. *J Pediatr* 99: 223–227

Papay R, Gaivin R, Jha A, McCune DF, McGrath JC, Rodrigo MC, Simpson PC, Doze VA, Perez DM (2006) Localization of the mouse alpha1A-adrenergic receptor (AR) in the brain: alpha1AAR is expressed in neurons, GABAergic interneurons, and NG2 oligodendrocyte progenitors. *J Comp Neurol* 497: 209–222

Patten SA, Jacobs-McDaniels NL, Zaouter C, Drapeau P, Albertson RC, Moldovan F (2012) Role of Chd7 in zebrafish: a model for CHARGE syndrome. *PLoS One* 7: e31650

Patten SA, Aggad D, Martinez J, Tremblay E, Petrillo J, Armstrong GA, La Fontaine A, Maios C, Liao M, Ciura S *et al* (2017) Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. *JCI Insight* 2: e97152

Payne S, Burney MJ, McCue K, Popal N, Davidson SM, Anderson RH, Scambler PJ (2015) A critical role for the chromatin remodeller CHD7 in anterior mesoderm during cardiovascular development. *Dev Biol* 405: 82–95

Pizzarelli R, Cherubini E (2011) Alterations of GABAergic signaling in autism spectrum disorders. *Neural Plast* 2011: 297153

Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, Ma'ayan A (2016) The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database* 2016: baw100

Rubenstein JL, Merzenich MM (2003) Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav* 2: 255–267

Ruwe WD, Naylor AM, Bauce L, Veale WL (1985) Determination of the endogenous and evoked release of catecholamines from the hypothalamus and caudate nucleus of the conscious and unrestrained rat. *Life Sci* 37: 1749–1756

Samarut E, Swaminathan A, Riche R, Liao M, Hassan-Abdi R, Renault S, Allard M, Dufour L, Cossette P, Soussi-Yanicostas N *et al* (2018) gamma-Aminobutyric acid receptor alpha 1 subunit loss of function causes genetic generalized epilepsy by impairing inhibitory network neurodevelopment. *Epilepsia* 59: 2061–2074

Samarut E, Chalopin D, Riche R, Allard M, Liao M, Drapeau P (2019) Individual knock out of glycine receptor alpha subunits identifies a specific requirement of glra1 for motor function in zebrafish. *PLoS One* 14: e0216159

Schmeisser K, Mansfeld J, Kuhlow D, Weimer S, Priebe S, Heiland I, Birringer M, Groth M, Segref A, Kanfi Y *et al* (2013) Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. *Nat Chem Biol* 9: 693–700

Schmeisser K, Fardghassemi Y, Parker JA (2017) A rapid chemical-genetic screen utilizing impaired movement phenotypes in *C. elegans*: input into genetics of neurodevelopmental disorders. *Exp Neurol* 293: 101–114

Schmeisser KFY, Parker JA (2017) A rapid chemical-genetic screen utilizing impaired movement phenotypes in *C. elegans*: input into genetics of neurodevelopmental disorders. *Exp Neurol* 293: 101–114

Schnetz MP, Handoko L, Akhtar-Zaidi B, Bartels CF, Pereira CF, Fisher AG, Adams DJ, Flicek P, Crawford GE, Laframboise T *et al* (2010) CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression. *PLoS Genet* 6: e1001023

Sethi A, Gu M, Gumusgoz E, Chan L, Yan KK, Rozowsky J, Barozzi I, Afzal V, Akiyama JA, Plajzer-Frick I *et al* (2020) Supervised enhancer prediction with epigenetic pattern recognition and targeted validation. *Nat Methods* 17: 807–814

Sloan CA, Chan ET, Davidson JM, Malladi VS, Strattan JS, Hitz BC, Gabdank I, Narayanan AK, Ho M, Lee BT *et al* (2016) ENCODE data at the ENCODE portal. *Nucleic Acids Res* 44: D726–D732

Smith IM, Nichols SL, Issekutz K, Blake K, Canadian Paediatric Surveillance P (2005) Behavioral profiles and symptoms of autism in CHARGE syndrome: preliminary Canadian epidemiological data. *Am J Med Genet A* 133A: 248–256

Sourbron J, Partoens M, Scheldeman C, Zhang Y, Lagae L, de Witte P (2019) Drug repurposing for Dravet syndrome in scn1Lab(-/-) mutant zebrafish. *Epilepsia* 60: e8–e13

Souriau J, Gimenes M, Blouin C, Benbrik I, Benbrik E, Churakowskyi A, Churakowskyi B (2005) CHARGE syndrome: developmental and behavioral data. *Am J Med Genet A* 133A: 278–281

Souza BR, Romano-Silva MA, Tropepe V (2011) Dopamine D2 receptor activity modulates Akt signaling and alters GABAergic neuron development and motor behavior in zebrafish larvae. *J Neurosc* 31: 5512–5525

Stewart AM, Nguyen M, Wong K, Poudel MK, Kalueff AV (2014) Developing zebrafish models of autism spectrum disorder (ASD). *Prog Neuropsychopharmacol Biol Psychiatry* 50: 27–36

Stiernagle T (2006) Maintenance of *C. elegans*. In *WormBook*, The *C. elegans* Research Community (ed) pp 1–11. Wormbook doi/10.1895/wormbook.1.101.1

Swaminathan A, Hassan-Abdi R, Renault S, Siekierska A, Riche R, Liao M, de Witte PAM, Yanicostas C, Soussi-Yanicostas N, Drapeau P *et al* (2018) Non-canonical mTOR-independent role of DEPDC5 in regulating GABAergic network development. *Curr Biol* 28: 1924–1937.e1925

Takata A, Miyake N, Tsurusaki Y, Fukai R, Miyatake S, Koshimizu E, Kushima I, Okada T, Morikawa M, Uno Y *et al* (2018) Integrative analyses of *de novo* mutations provide deeper biological insights into autism spectrum disorder. *Cell Rep* 22: 734–747

Van Nostrand JL, Brady CA, Jung H, Fuentes DR, Kozak MM, Johnson TM, Lin CY, Lin CJ, Swiderski DL, Vogel H *et al* (2014) Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature* 514: 228–232

Vansal SS, Feller DR (1999) Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. *Biochem Pharmacol* 58: 807–810

Verduzco D, Amatruda JF (2011) Analysis of cell proliferation, senescence, and cell death in zebrafish embryos. *Methods Cell Biol* 101: 19–38

Vithayathil J, Pucilowska J, Landreth GE (2018) ERK/MAPK signaling and autism spectrum disorders. *Prog Brain Res* 241: 63–112

Watanabe Y, Takechi K, Fujiwara A, Kamei C (2010) Effects of antiepileptics on behavioral and electroencephalographic seizure induced by pentetrazol in mice. *J Pharmacol Sci* 112: 282–289

Wellman PJ, Miller DK, Ho DH (2003) Noradrenergic modulation of ephedrine-induced hypophagia. *Synapse* 48: 18–24

Westerfield M (1993) *The zebrafish book : a guide for the laboratory use of zebrafish (Brachydanio rerio)*, Eugene, OR: M. Westerfield

Whittaker DE, Riegman KL, Kasah S, Mohan C, Yu T, Sala BP, Hebaishi H, Caruso A, Marques AC, Michetti C *et al* (2017) The chromatin remodeling factor CHD7 controls cerebellar development by regulating reelin expression. *J Clin Investig* 127: 874–887

Wullimann MF, Knipp S (2000) Proliferation pattern changes in the zebrafish brain from embryonic through early postembryonic stages. *Anat Embryol (Berl)* 202: 385–400

Xu DQ, Wang Z, Wang CY, Zhang DY, Wan HD, Zhao ZL, Gu J, Zhang YX, Li ZG, Man KY *et al* (2016) PAQR3 controls autophagy by integrating AMPK signaling to enhance ATG14L-associated PI3K activity. *The EMBO journal* 35: 496–514

Zentner GE, Layman WS, Martin DM, Scacheri PC (2010) Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. *Am J Med Genet A* 152A: 674–686

Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai O, Liu W, Xie X, Wang Z *et al* (2010) RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. *Oncogene* 29: 5404–5415

Zhen M, Samuel AD (2015) *C. elegans* locomotion: small circuits, complex functions. *Curr Opin Neurobiol* 33: 117–126